Public health and national security are threatened by record numbers of generic drug shortages that are primarily caused by manufacturer quality problems, ~80% of US drugs originating from China or India, and growing evidence of problems with generic drug quality and safety. Conservative estimates suggest that the lowest quality 10% of generic drugs lead to over $18 billion in avoidable public health costs annually just in chronic disease. In 2012, FDA identified that the root cause of drug supply problems is “the inability of the [generic drug] market to observe and reward quality” because only price drives the dangerously commoditized generic drug market. Recent analyses, Congressional hearings, and a NASEM convening sponsored by DoW, have all reached the same conclusion. To address such issues, multiple government agencies and large private health systems have recommended revising pharmacy purchasing models to increase emphasis on quality, not simply lowest cost. Furthermore, multiple independent drug quality programs have begun in the past few years, with one of the largest being at the Department of War (DoW). This DoW study conducts broad market sweeps of available brand and generic manufacturers of critical medicines and utilizes independent chemical testing of these drugs to generate actionable transparency to drug quality. The “Red / Yellow / Green” scores are connected to National Drug Codes utilized not only by the Military Health System, but all health systems nationwide. By creating much-needed transparency in drug quality, this study enables conscientious manufacturers to be able to better compete and allows major purchasers of drugs, both government and private, to reward good manufacturers and exclude lower quality medicines. Recent integration with location data shows that lower quality medicines tend to concentrate in India and China, whereas higher quality medication tends to be made in USA-based facilities. Therefore, incentivizing the purchase of “green”-rated medications and avoiding “red”-rated options in pharmacy procurement can create a powerful demand signal which incentivizes quality and American-made medicines. This can substantially help with reshoring efforts and strengthen national security. Final results for a handful of medicines and over 400 generic drug products were analyzed and show a majority of products rated "green" but approximately 15% are "red" for a variety of issues including clinically concerning dissolution rates and high levels of toxins.